NEW HAVEN, Conn., Feb. 9, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will be presenting a company overview at the upcoming investor conferences:
- 13th Annual BIO CEO & Investor Conference on Tuesday, February 15, 2011 at 11:30 a.m. ET at the Waldorf=Astoria in New York City;
- Leerink Swann Hot Topics and Therapeutics Roundtable Conference on Wednesday, February 16, 2011 at 2:40 p.m. ET at the Roosevelt Hotel in New York City; and
- 31st Annual Cowen & Company Healthcare Conference on March 7, 2011 at 2:30 p.m. at the Marriott Copley Place in Boston.
The live audio broadcasts and the subsequent archived webcasts of the Company's presentations will be available on the Company's website, , under the "News Center" section. The audio recording will be archived there for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.
About Achillion
Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease –hepatitis C and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit or call 1-203-624-7000.
ACHN-G
CONTACT: Mary Kay Fenton Achillion Pharmaceuticals, Inc. Tel. (203) 624-7000 mfenton@achillion.com Investor Relations: Anne Marie Fields Lippert/Heilshorn & Associates, Inc. Tel. (212) 838-3777 afields@lhai.com